跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2010-019883-36-DE
EUCTR2010-019883-36-DE进行中（未招募）不适用

A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

ovartis Pharma Services AG0 个研究点目标入组 55 人开始时间: 2011年5月13日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
不适用
状态
进行中（未招募）
入组人数
55
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Written informed consent must be obtained before any assessment is performed
  • •2. Male or female 18 years of age or older who are unable to bear children and females of child bearing potential not disqualified as per Exclusion Criterion 1 (below)
  • •3. WHO Functional Class II or III
  • •4. PVR > 800 dyn.s/cm5 at screening
  • •5. A current diagnosis of Pulmonary Arterial Hypertension according to the Dana Point 2008 Meeting: WHO Diagnostic Group I, idiopathic or heritable (familial or sporadic) PAH, PAH associated with collagen vascular disease including systemic sclerosis, rheumatoid arthritis, mixed connective tissue diseases, and overlap syndrome. PAH following one year repair of congenital heart defect (ASD, VSD or PDA), or PAH associated with diet therapies or other drugs
  • •6. Inadequate clinical response despite stabilization on one or more class(es) of PAH drug [e.g., PDE5 inhibitor, endothelin receptor blocker, vasodilator prostaglandin (systemic, inhaled or oral)]
  • •7. Stabilization of pulmonary hypertension medications defined as observed for = 2 months on approved therapeutic dose of at least one PAH drug and still symptomatic with WHO functional Class II or III performance.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 50
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 5

排除标准

  • •1. Other diagnosis of PAH in WHO Diagnostic Group 1 including congenital systemic to
  • •pulmonary shunts
  • •2. A diagnosis of PAH associated with: venous hypertension (WHO Diagnostic Group II, including LVEF < 45%), hypoxia (WHO Diagnostic Group III), chronic pulmonary thromboembolic disease (WHO Diagnostic Group IV) or other miscellaneous causes (WHO Diagnostic Class V, which includes sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels, glycogen storage disease, Gaucher’s disease, myeloproliferative disorders)
  • •3. Diagnosis of pulmonary artery or vein stenosis
  • •4. Pre-existing lung disease including parasitic diseases affecting lungs, congenital abnormalities of the lungs, COPD, thorax or diaphragm or bronchial asthma
  • •5. WHO Class IV
  • •6. Previous therapeutic radiation of lungs or mediastinum
  • •7. In treatment with chronic nitric oxide therapy
  • •8. An advanced, severe, or unstable disease of any type that may interfere with the primary and secondary endpoint evaluations
  • •9. Having undergone atrial septostomy in the 3 months prior to the screening visit
  • •10. Previously undergone radiofrequency catheter ablation for atrial or sinus arrhythmias in the 3 months prior to screening visit
  • •11. History of ventricular tachycardia, ventricular fibrillation or ventricular flutter
  • •12. History of left-heart disease.
  • •13. Atrial fibrillation or history of atrial fibrillation in the previous 3 months
  • •14. Having syncope in the 3 months prior to the screening visit
  • •15. History of previous myocardial infarction, unstable angina, or clinically significant bradycardia (<60 bpm and accompanied by clinical symptoms)
  • •16. QRS > 120 ms or > 140 ms in the presence of bundle branch block
  • •17. Current or history of consistently prolonged QTcF (2 or more ECGs in the prior 12 months in the absence of a right bundle branch block or QTcF>450 ms for males and > 470 ms for females at screening); family history of long QT syndrome
  • •18. History of Torsades de Pointes
  • •19. Use of drugs known to prolong the QT interval or known to be strong CYP3A4 inhibitors
  • •20. Untreated or inadequately controlled hypokalemia (<3.5 mmol/L) or hypomagnesemia (<0.65 mmol/L) at the screening visit (Visit 1)
  • •21. Uncontrolled systemic arterial hypertension, systolic > 160 mm Hg or diastolic >90 mm Hg
  • •22. Evidence of clinically significant hepatic impairment
  • •23. Diagnosis of Hepatitis B or C
  • •24. Hemoglobin < 100 g/L (10 g/dL) at the screening visit (Visit 1)
  • •25. History of sickle cell anemia
  • •26. Deficient thrombocyte function, thrombocytopenia < 50 x109/L (50 x 103/µL)
  • •27. Deficiencies of blood coagulation, inherited or acquired blood coagulation disorders, factor XII, factor XIII
  • •28. Disseminated intravascular coagulation (DIC)
  • •29. Evidence of major bleeding or intracranial hemorrhage
  • •30. History of latent bleeding risk such as diabetic retinopathy, gastrointestinal bleeding due to gastric or duodenal ulcers, or colitis ulcerosa
  • •31. History of elevated intracranial pressure
  • •32. History of immunodeficiency diseases, including HIV
  • •33. History of pancreatitis or serum amylase or lipase = 1.5 x ULN at screening or baseline visits
  • •34. Previous treatment with nilotinib
  • •35. Use of other investigational drugs (including study drug) at the time of enrollment, of within 30 days or 5 half-lives of enrollment, whichever is longer
  • •36. History of hypersensitivity to nilotinib or to drugs of similar chemical classes
  • •37. Medically diagnosed symptomatic lactose i

研究者

相似试验

进行中（未招募）
不适用
DPulmonary Arterial Hypertension (PAH)MedDRA version: 14.1Level: PTClassification code 10037400Term: Pulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
EUCTR2010-019883-36-ITOVARTIS FARMA55
进行中（未招募）
不适用
A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertension (PAH) Class II or III patients remaining symptomatic despite at least one PAH-specific therapy.MedDRA version: 12.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertension
EUCTR2010-019883-36-HUovartis Pharma AG66
进行中（未招募）
1 期
A 24-week study to compare efficacy and safety of oral masitinib to placebo in the treatment of patients with severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatmentsevere mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatmentMedDRA version: 20.1Level: PTClassification code 10075217Term: Mast cell activation syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disorders
EUCTR2021-005406-96-BEAB Science78
进行中（未招募）
1 期
A 24-week study to compare efficacy and safety of oral masitinib to placebo in the treatment of patients with severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatmentsevere mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatmentMedDRA version: 20.1Level: PTClassification code 10075217Term: Mast cell activation syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disorders
EUCTR2021-005406-96-DEAB Science78
进行中（未招募）
1 期
Study to evaluate safety and efficacy of Dapagliflozin in patients with type 2 diabetes mellitus aged 10-24 years
EUCTR2015-005041-31-ROAstraZeneca AB70